Under the terms of the partnership, Abbott will utilise its distribution infrastructure to promote MSD’s sitagliptin-based products — Januvia, Janumet, and Janumet XR. These brands continue to lead the DPP-4 inhibitor segment, even after the patent expiry in July 2022 that opened the market to generics and led to significant price competition.
Sitagliptin, first introduced in India in 2008, has played a key role in managing type 2 diabetes by lowering HbA1c levels and improving blood sugar control. Despite rising competition from generics, MSD has maintained a strong position in the value segment of this category.
India’s oral anti-diabetes market is currently valued at ₹12,500 crore, with DPP-4 inhibitors contributing around ₹4,000 crore. Globally, sitagliptin accounts for more than 60% of the DPP-4 inhibitor market share, reinforcing its standing as a standard treatment option.
Over 101 million people in India live with the disease, and an additional 136 million are at risk. Non-communicable diseases, including diabetes, account for nearly 60% of all deaths in the country, making access to effective treatment options a public health priority.
Alos Read: Zydus Lifesciences Ahmedabad oncology injectable plant gets two FDA observations
Shares of Abbott India dropped ₹293.35 (-0.92%), ending the day at ₹31,510 on the BSE today (June 18).
(Edited by : Shoma Bhattacharjee)
First Published: Jun 18, 2025 7:10 PM IST
